Denosumab is a monoclonal antibody used for prevention of skeletal-related events (SREs) in patients with bone metastases from solid tumors. Hypocalcemia is a rare and dangerous side effect of the drug Denosumab. We present a case of a patient with metastatic prostate cancer who developed severe hypocalcemia after the administration of the drug. The patient's vitamin D levels were low when checked after administration of the drug, which likely predisposed him to the development of hypocalcemia. He was placed on high doses of oral and intravenous (IV) calcium and vitamin D without any appreciable response in the serum calcium level. His ionized calcium remained below 0.71 mmol/L despite very high doses of oral and IV calcium supplements. During the hospital course, he developed hydronephrosis from the spread of a tumor and did not want to undergo percutaneous nephrostomy tube placement; therefore, it was decided to dialyse him for acute renal failure and to correct his hypocalcemia. Checking calcium and vitamin D levels prior to the administration of Denosumab is vital in preventing hypocalcemia. If hypocalcemia is severe and not responsive to high doses of vitamin D, oral and IV calcium, then hemodialysis with a high calcium bath can correct this electrolyte abnormality.
e17012 Background: The overall prognosis for most acute myeloid leukemia (AML) patients remains poor. The majority of adult patients (pts) with AML will ultimately need allogeneic stem cell transplant (allo-SCT). Limited data is available comparing epidemiology and treatment outcomes between uninsured and insured pts with AML. We describe a retrospective analysis of adult pts with AML treated at our institution. Methods: From January 2000 to June 2011 we identified 239 pts with AML, of which 185 met inclusion criteria. Patients were classified as having private insurance, public insurance (Medicaid and Medicare), or no insurance. Primary outcomes were overall survival at follow up (OS), complete remission (CR), and percent of pts receiving allo-SCT. Kaplan-Meier analysis was used to estimate survival rates. Results: Of the 185 pts studied, 146 (81%) were white, 16 (9%) African-American and 11 (6%) were Native American. The median age at diagnosis was 49 years. 75 pts had private insurance at the time of diagnosis, 70 had public insurance, and 33 were uninsured. Of those receiving allo-SCT (n=60; 38 male) 48% had private insurance, 30% public, and 22% were uninsured. Whether a patient underwent allo-SCT did not differ according to insurance source (p=0.2189) nor to status at follow-up (p= 0.6480). The proportion of patients achieving CR was higher among those undergoing allo-SCT (p=0.0002). Median OS was 920 days for those who underwent allo-SCT and 192 days for those who did not (p< 0.0001). Median OS did not differ by insurance type (p = 0.1454). The proportion of patients achieving CR did not differ by insurance type (p=0.2665) (66.7% of those with private, 62.7% of those with public, and 78.8% of those with no insurance). Conclusions: For the population referred to our institution, a tertiary referral center for the state, there were no differences in treatment outcomes or in the percent of pts receiving allo-SCT when pts were stratified according to insurance source. Further analysis of this dataset will identify the impact of pretreatment variables stratified by type of insurance.
Introduction Insurance status has been found to affect treatment outcomes in various solid tumors. However, less data is available in patients with acute myeloid leukemia (AML). We conducted a comprehensive retrospective analysis to further investigate whether insurance status affects treatment outcomes in AML patients. Our analyses evolved to explore the role potential biochemical and clinical pre-treatment variables play in affecting treatment outcomes and predicting known cytogenetic risk groups. Methods From 2000 to 2011 we identified 269 patients with AML at The University of Oklahoma Health Sciences Center. A total of 217 patients with usable medical records were included in the final analysis. In the study, 28 pretreatment variables were examined to assess their effect on prognosis in terms of treatment outcomes and their ability to predict cytogenetic/molecular risk status. Cytogenetic risk groups were created based on the National Comprehensive Cancer Network (NCCN) guidelines algorithm. Primary outcomes were complete remission (CR), relapse, and overall survival (OS) rates. In order to assess survival, Kaplan-Meier curves and log rank tests of equality were performed on categorical variables. Cox proportional hazard models were used to assess continuous variables. A multivariate Cox proportional hazard model was created to explore associations between overall survival times with all covariates. Pre-treatment variables were then used to predict cytogenetic risk status using a multinomial logistic regression. Results Of the 217 patients (52.2% males, 47.8% females) included in the study, 81.5% were white, 9.0% African American, and 6.2% Native American. Median age at diagnosis was 51.0 years. 36.3% had private insurance, 45.8% had public insurance, and 17.3% were uninsured. There was no significant association found between insurance status and treatment outcomes (CR, OS, and relapse rates). Cytogenetic risk status was independently associated with insurance status (table 1). Cytogenetic risk status was also significantly related to complete remission (p=0.0007), status at last follow up (p = 0.0405), and overall survival (p = 0.0002 for better-risk and p < 0.0001 for intermediate-risk, compared to poor-risk group). Among 28 tested variables, we found 3 factors significantly predict cytogenetic/molecular risk status. Having the better-risk group as the reference group, diabetes (OR-12.7, 95% CI = 1.44-111.7) and elevated creatinine (OR- 0.07, 95% CI = 0.0-0.95) were predictive for intermediate-risk, where as diabetes (OR-6.9, 95% CI = 1.07-44.8) and elevated uric acid (OR- 0.60, 95% CI = 0.39-0.91) were predictive for poor-risk group. Conclusion Based on cytogenetic and molecular classification, our results on survival analysis are consistent with previous reported studies (figure 1). There was no association between treatment outcomes and insurance status. Among the 28 pretreatment variables studied, we found that diabetes, uric acid, and creatinine might be useful markers in predicting cytogenetic risk category. This could aid in risk-adaptive treatment plans before cytogenetic tests become available or tests prove to be unfeasible to be done. Larger studies are needed to corroborate our findings. Disclosures: No relevant conflicts of interest to declare.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.